While the low levels of AD biomarkers captured in our sample do not meet the cut-offs to predict cognitive decline or dementia (Blennow et al., 2019; Brum et al., 2022), our findings indicate that biomarker levels within this range may affect brain structure when considering additional contributing factors such as estrogens and APOE genotype. The gene discussed is APOE; the disease is Alzheimer disease.